Investment Thesis
Imunon exhibits critical financial distress with only $500K in annual revenue while burning $4.3M in free cash flow, providing less than 12 months of operational runway at current burn rates. The company carries $6.1M in long-term debt against $4.8M cash and negative interest coverage of -21.9x, creating acute solvency risk. Without significant revenue acceleration or capital restructuring, insolvency is a material threat within the next 12-18 months.
Strengths
- Maintains positive cash balance of $4.8M providing near-term liquidity buffer
- Current ratio of 1.59x indicates acceptable short-term liquidity on surface
- Improvement in EPS from -$2.08 to -$0.84 YoY shows relative operational improvement
Risks
- Operating cash flow of -$4.0M annually with only $4.8M cash creates ~12-month solvency window
- Debt-to-equity ratio of 1.81x with negative interest coverage (-21.9x) indicates inability to service debt from operations
- Revenue of $500K with 0% growth and operating losses of $4.3M suggest pre-commercial or failed product pipeline
- Long-term debt of $6.1M exceeds total equity of $3.4M, creating refinancing risk
- No insider purchases in 90 days despite financial distress suggests lack of management confidence
- Pharmaceutical company with minimal revenue indicates failed or delayed product commercialization
Key Metrics to Watch
- Quarterly cash burn rate and months of cash remaining
- Revenue growth trajectory and evidence of product commercialization
- Debt refinancing schedule and covenant compliance status
- Insider buying activity indicating management confidence
- Operating cash flow path to positive territory
Financial Metrics
Revenue
500.0K
Net Income
-4.2M
EPS (Diluted)
$-0.84
Free Cash Flow
-4.3M
Total Assets
8.0M
Cash
4.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-861.3%
Net Margin
-849.8%
ROE
-126.5%
ROA
-53.0%
FCF Margin
-853.1%
Balance Sheet & Liquidity
Current Ratio
1.59x
Quick Ratio
1.59x
Debt/Equity
1.81x
Debt/Assets
58.1%
Interest Coverage
-21.85x
Long-term Debt
6.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T08:40:38.346394 |
Data as of: 2026-03-31 |
Powered by Claude AI